Suchergebnisse - Schey, Steve

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5 von Schey, Steve, Montero, Luis Felipe Casado, Stengel-Tosetti, Chloe, Gibson, Craig J., Dhanasiri, Sujith

Volltext Volltext Volltext

Risk of relapse of multiple myeloma following kidney transplantation von Shah, Sapna, Ibrahim, Maria, Delaney, Michael, Schey, Steve, Bygrave, Ceri, Streetly, Matthew, Benjamin, Reuben

Volltext Volltext Volltext

GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death von Streetly, Matthew J., Maharaj, Lenushka, Joel, Simon, Schey, Steve A., Gribben, John G., Cotter, Finbarr E.

Volltext Volltext Volltext

Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods von Ramsenthaler, Christina, Gao, Wei, Siegert, Richard J., Schey, Steve A., Edmonds, Poly M., Higginson, Irene J.

Volltext Volltext Volltext

The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma von Davies, Joanna M., Osborne, Thomas R., Edmonds, Polly M., Schey, Steve A., Devereux, Steve, Higginson, Irene J., Ramsenthaler, Christina

Volltext Volltext Volltext